Synlogic, Inc., (Nasdaq: SYBX) announced that it is discontinuing development of SYNB1020, an early stage clinical product candidate for the ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Hot Corp. News

Synlogic Inc. (SYBX) PT Lowered to $13 at H.C. WainwrightAugust 21, 2019 7:17 AM Synlogic Inc. (SYBX) PT Lowered to $14 at WedbushAugust 21, 2019 4:16 AM Synlogic Inc. (SYBX) PT Lowered to $6 at JefferiesAugust 21, 2019 4:16 AM Synlogic Discontinues Development of SYNB1020 to Treat HyperammonemiaAugust 20, 2019 6:00 AM